



Seán Canney, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

1st January 2022

PQ: 63093/21

To ask the Minister for Health the progress that has been made in addressing delays in progressing paperwork for a drug (details supplied); if his attention has been drawn to the difficulties that these delays are causing for persons with chronic migraine; and if he will make a statement on the matter. -Seán Canney

Details Supplied: TEVA drug AJOVY

Dear Deputy Canney,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 63093/21), which you submitted to the Minister for Health for response.

Reimbursement of Fremanezumab, is supported under the High Tech Arrangement via a Managed Access Protocol overseen by the HSE Medicines Management Programme (MMP). The HSE has no role in organising or underpinning the Pharmacy Early Access Schemes.

Under the Managed Access Protocol, reimbursement of Erenumab and Fremanezumab (calcitonin gene-related peptide (CGRP) monoclonal antibodies (MABs)) is supported for the following subgroup of the licensed population

- Prophylaxis of chronic migraine in adults who have failed three or more prophylactic treatments.

Approved prescribers are required to apply for reimbursement approval on an individual basis through the online application system. When a patient meets the criteria outlined in the Managed Access Protocol, they are approved for reimbursement under High Tech Arrangements. All applications received for review by the MMP are dealt with within a very short timeframe when all the requisite information to enable a positive decision is supplied by the prescriber.

Further information can be found online on the MMP webpage at <https://www.hse.ie/eng/about/who/cspd/ncps/medicines-management/managed-access-protocols/cgrp-mabs/cgrp-mabs.html>.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Suzanne Doyle', written over a horizontal line.

Suzanne Doyle
Primary Care Eligibility & Reimbursement Service